DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) said its president and chief executive officer, Oren Gilad, will provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026.
The presentation is scheduled for 8:40 a.m. EST and will be held virtually, the company announced.
A live webcast will be available at https://event.summitcast.com/ and will remain accessible for 90 days. The webcast will also be available on the Investors page of Aprea’s website under “News & Events” at https://ir.aprea.com/.
The Oppenheimer conference is scheduled for February 25-26, 2026.
Aprea is a clinical-stage biopharmaceutical company developing therapies designed to target cancer cell vulnerabilities while limiting damage to healthy cells.
The company’s lead programs include APR-1051, an oral small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications, including ovarian, endometrial, colorectal and head and neck cancers.
Investors seeking one-on-one meetings with Aprea management during the conference were advised to contact their Oppenheimer representative, according to the announcement.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.